A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients

Abstract Ovarian cancer is one of the most common cancers in women and is often diagnosed as advanced stage because of the subtle symptoms of early ovarian cancer. To identify the somatic alterations and new biomarkers for the diagnosis and targeted therapy of Chinese ovarian cancer patients, a tota...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yingli Zhang, Xiaoliang Shi, Jiejie Zhang, Xi Chen, Peng Zhang, Angen Liu, Tao Zhu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/67c01b7001e34e93ad0ee16f501600a7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:67c01b7001e34e93ad0ee16f501600a7
record_format	dspace
spelling	oai:doaj.org-article:67c01b7001e34e93ad0ee16f501600a72021-12-02T14:01:33ZA comprehensive analysis of somatic alterations in Chinese ovarian cancer patients10.1038/s41598-020-79694-02045-2322https://doaj.org/article/67c01b7001e34e93ad0ee16f501600a72021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-79694-0https://doaj.org/toc/2045-2322Abstract Ovarian cancer is one of the most common cancers in women and is often diagnosed as advanced stage because of the subtle symptoms of early ovarian cancer. To identify the somatic alterations and new biomarkers for the diagnosis and targeted therapy of Chinese ovarian cancer patients, a total of 65 Chinese ovarian cancer patients were enrolled for detection of genomic alterations. The most commonly mutated genes in ovarian cancers were TP53 (86.15%, 56/65), NF1 (13.85%, 9/65), NOTCH3 (10.77%, 7/65), and TERT (10.77%, 7/65). Statistical analysis showed that TP53 and LRP1B mutations were associated with the age of patients, KRAS, TP53, and PTEN mutations were significantly associated with tumor differentiation, and MED12, LRP2, PIK3R2, CCNE1, and LRP1B mutations were significantly associated with high tumor mutational burden. The mutation frequencies of LRP2 and NTRK3 in metastatic ovarian cancers were higher than those in primary tumors, but the difference was not significant (P = 0.072, for both). Molecular characteristics of three patients responding to olapanib supported that BRCA mutation and HRD related mutations is the target of olaparib in platinum sensitive patients. In conclusion we identified the somatic alterations and suggested a group of potential biomarkers for Chinese ovarian cancer patients. Our study provided a basis for further exploration of diagnosis and molecular targeted therapy for Chinese ovarian cancer patients.Yingli ZhangXiaoliang ShiJiejie ZhangXi ChenPeng ZhangAngen LiuTao ZhuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yingli Zhang Xiaoliang Shi Jiejie Zhang Xi Chen Peng Zhang Angen Liu Tao Zhu A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients
description	Abstract Ovarian cancer is one of the most common cancers in women and is often diagnosed as advanced stage because of the subtle symptoms of early ovarian cancer. To identify the somatic alterations and new biomarkers for the diagnosis and targeted therapy of Chinese ovarian cancer patients, a total of 65 Chinese ovarian cancer patients were enrolled for detection of genomic alterations. The most commonly mutated genes in ovarian cancers were TP53 (86.15%, 56/65), NF1 (13.85%, 9/65), NOTCH3 (10.77%, 7/65), and TERT (10.77%, 7/65). Statistical analysis showed that TP53 and LRP1B mutations were associated with the age of patients, KRAS, TP53, and PTEN mutations were significantly associated with tumor differentiation, and MED12, LRP2, PIK3R2, CCNE1, and LRP1B mutations were significantly associated with high tumor mutational burden. The mutation frequencies of LRP2 and NTRK3 in metastatic ovarian cancers were higher than those in primary tumors, but the difference was not significant (P = 0.072, for both). Molecular characteristics of three patients responding to olapanib supported that BRCA mutation and HRD related mutations is the target of olaparib in platinum sensitive patients. In conclusion we identified the somatic alterations and suggested a group of potential biomarkers for Chinese ovarian cancer patients. Our study provided a basis for further exploration of diagnosis and molecular targeted therapy for Chinese ovarian cancer patients.
format	article
author	Yingli Zhang Xiaoliang Shi Jiejie Zhang Xi Chen Peng Zhang Angen Liu Tao Zhu
author_facet	Yingli Zhang Xiaoliang Shi Jiejie Zhang Xi Chen Peng Zhang Angen Liu Tao Zhu
author_sort	Yingli Zhang
title	A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients
title_short	A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients
title_full	A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients
title_fullStr	A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients
title_full_unstemmed	A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients
title_sort	comprehensive analysis of somatic alterations in chinese ovarian cancer patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/67c01b7001e34e93ad0ee16f501600a7
work_keys_str_mv	AT yinglizhang acomprehensiveanalysisofsomaticalterationsinchineseovariancancerpatients AT xiaoliangshi acomprehensiveanalysisofsomaticalterationsinchineseovariancancerpatients AT jiejiezhang acomprehensiveanalysisofsomaticalterationsinchineseovariancancerpatients AT xichen acomprehensiveanalysisofsomaticalterationsinchineseovariancancerpatients AT pengzhang acomprehensiveanalysisofsomaticalterationsinchineseovariancancerpatients AT angenliu acomprehensiveanalysisofsomaticalterationsinchineseovariancancerpatients AT taozhu acomprehensiveanalysisofsomaticalterationsinchineseovariancancerpatients AT yinglizhang comprehensiveanalysisofsomaticalterationsinchineseovariancancerpatients AT xiaoliangshi comprehensiveanalysisofsomaticalterationsinchineseovariancancerpatients AT jiejiezhang comprehensiveanalysisofsomaticalterationsinchineseovariancancerpatients AT xichen comprehensiveanalysisofsomaticalterationsinchineseovariancancerpatients AT pengzhang comprehensiveanalysisofsomaticalterationsinchineseovariancancerpatients AT angenliu comprehensiveanalysisofsomaticalterationsinchineseovariancancerpatients AT taozhu comprehensiveanalysisofsomaticalterationsinchineseovariancancerpatients
_version_	1718392144479125504

A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients

Ejemplares similares